SCHEMBL18825463

SCHEMBL18825463

CCc1cnc(N2CCC(COc3ccc(C4=CCC(C(=O)N5CCCCC5)CC4)cn3)CC2)nc1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.44
▸ KCNH2 Q12809 2/20 0.36
▸ ACACB O00763 2/20 0.34
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ PREP P48147 1/20 0.33
▸ RIPK1 Q13546 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ LIPE Q05469 1/20 0.33
▸ EP300 Q09472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18825441 0.99 GPR119 (0.44) GPR119KCNH2ACACBRIPK1ATM
SCHEMBL18825471 0.93 GPR119 (0.43) GPR119KCNH2ACACBLIPE
SCHEMBL18825339 0.93 GPR119 (0.43) GPR119KCNH2ACACBLIPEEP300
SCHEMBL18825384 0.92 GPR119 (0.43) GPR119KCNH2ACACB
SCHEMBL18825515 0.92 GPR119 (0.43) GPR119KCNH2ACACB
SCHEMBL17234761 0.91 GPR119 (0.51) GPR119KCNH2ACACB
Hydrochloric Acid SCHEMBL18574765 0.90 GPR119 (0.51) GPR119KCNH2ACACB
SCHEMBL18843757 0.90 GPR119 (0.46) GPR119ACACBEP300
SCHEMBL17234760 0.90 GPR119 (0.52) GPR119KCNH2ACACB
Hydrochloric Acid SCHEMBL18574746 0.89 GPR119 (0.51) GPR119KCNH2ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient HYUNDAI PHARM CO., LTD. (KR) 2020-07-28 — — US claimed
US-20180318274-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2018-11-08 — — US claimed
EP-3352750-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT Hyundai Pharm Co., Ltd. (KR) 2018-08-01 — — EP claimed
WO-2017078352-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2017-05-11 — — WO claimed
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient HYUNDAI PHARM CO., LTD. (KR) 2020-07-28 — — US disclosed
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient HYUNDAI PHARM CO., LTD. (KR) 2020-07-28 — — US disclosed
US-20180318274-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2018-11-08 — — US disclosed
EP-3352750-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT Hyundai Pharm Co., Ltd. (KR) 2018-08-01 — — EP disclosed
WO-2017078352-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2017-05-11 — — WO disclosed
WO-2017078352-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT HYUNDAI PHARM CO., LTD. (KR) 2017-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723699-B2 Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 1981/4885ACACB 632/4885
US-20180318274-A1 CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 1981/4885ACACB 632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback